Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
Summary
EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.
Description
EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source